KRYSTAL-7: Efficacy and Safety of Adagrasib with Pembrolizumab in Patients With Advanced KRASG12C Mutated NSCLC

Opinion
Video

KRYSTAL-7 is a study exploring the efficacy of adding adagrasib to first-line pembrolizumab in patient with NSCLC with varying PD-L1 expression levels, showing promising response rates and progression-free survival, but also adverse events like hepatotoxicity.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Tim Cortese
April 23rd 2025
Article

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Tim Cortese
April 20th 2025
Article

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC

Roman Fabbricatore
April 14th 2025
Article

Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

Disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.

Plasma-Based MRD Analysis May Predict Recurrence in EGFR-Mutant NSCLC

Roman Fabbricatore
April 12th 2025
Article

A disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.